POSSIBLE ROLE OF MITOCHONDRIAL DNA MUTATIONS IN THE ETIOLOGY AND PATHOGENESIS OF DOWN’S SYNDROME
Arbuzova S*
*Corresponding Author: Dr. Svetlana Arbuzova, Interregional Medico-Genetic Center, Central Hospital, Clinic number 1, 57 Artem Street, 83000 Donetsk, Ukraine; Tel: +380-62-2-90-2442; E-mail: s.arbuzova@lb.dn.ua.
page: 11

DISCUSSION

There is a growing body of evidence supporting the hypothesis that mtDNA mutations are involved in DS etiology, especially where there is familial recurrence. A commonly proposed alternative explanation of DS recur­rence is mosaicism, although it cannot account for the familial aggregation of DS with other aneuploidies, and the fact that mosaicism can occur in successive genera­tions [24,25] does not exclude the possibility that mtDNA mutations may cause both full aneuploidy and mosaicism itself.


In families with one affected child, mosaicism of pa­rental lymphocytes or fibroblasts is found in under 5% of cases [26]. It is more common in families with DS recur­rence, but even then, the incidence is relatively low. For example, one study found mosaicism in only five out of 22 families, even using DNA analysis which, unlike cyto­genetic methods, may detect low-level mosaicism [19]. There are case reports of gonadal mosaicism with a normal chromosome complement in peripheral blood or fibro­blasts, but the proportion of families with such errors is not known. However, even a high percentage of trisomic oo­cytes cannot explain all recurrences: when all are trisomic, half the gametes would be normal. And a serious criticism of all published mosaicism studies is that they did not include controls from unaffected families. Studies on pre-implantation genetic diagnosis show that aneuploidy in oocytes and embryos is not a rare event and it increases markedly with maternal age, being the consequence of both trisomic germ line and further disruption in meiotic division [27].

Although there is evidence for mtDNA involvement in DS pathogenesis, it is widely believed that the oxidative stress in DS is due to a direct gene dosage effect resulting from a 50% increase in the activity of SOD-1. However, examination of the available evidence reveals many con­tradictions [28].

The association between trisomy 21 and SOD-1 activ­ity is not straight-forward: some DS cases with partial trisomy 21, a translocation or mosaic replication, have normal SOD-1; some cases of partial trisomy 21 without DS have increased SOD-1 [8,29]; and in some DS indi­viduals with partial trisomy 21 the SOD-1 locus is not triplicated [30]. In DS cases, SOD-1 levels vary according to cell or tissue type: in blood cells and fibroblasts activity is generally increased, albeit to a variable extent, while in some individuals who have normal activity and plasma SOD‑1, activity is markedly decreased [29,31-34]. Fur­thermore, it is far from clear that increased SOD‑1 in DS is a cause of oxidative stress. In one series of DS cases it was found that while SOD‑1 levels fell with age, lipid peroxidation increased [9,12]. An alternative and compel­ling interpretation of the data on elevated SOD‑1 activity is that it has a protective rather than a harmful effect, since the increase of this scavenger is of benefit for the homeostasis between generated reactive oxygen metabo­lites and their propagation. In this interpretation SOD‑1 activity in DS is increased as a response to oxidative stress, and unlike unaffected individuals, activity can readily be increased because of the additional copy of the gene. In conclusion, there is more evidence in favor of a role for mtDNA mutations in both DS etiology and patho­genesis than for any of the alternative explanations.




Number 27
VOL. 27 (2), 2024
Number 27
VOL. 27 (1), 2024
Number 26
Number 26 VOL. 26(2), 2023 All in one
Number 26
VOL. 26(2), 2023
Number 26
VOL. 26, 2023 Supplement
Number 26
VOL. 26(1), 2023
Number 25
VOL. 25(2), 2022
Number 25
VOL. 25 (1), 2022
Number 24
VOL. 24(2), 2021
Number 24
VOL. 24(1), 2021
Number 23
VOL. 23(2), 2020
Number 22
VOL. 22(2), 2019
Number 22
VOL. 22(1), 2019
Number 22
VOL. 22, 2019 Supplement
Number 21
VOL. 21(2), 2018
Number 21
VOL. 21 (1), 2018
Number 21
VOL. 21, 2018 Supplement
Number 20
VOL. 20 (2), 2017
Number 20
VOL. 20 (1), 2017
Number 19
VOL. 19 (2), 2016
Number 19
VOL. 19 (1), 2016
Number 18
VOL. 18 (2), 2015
Number 18
VOL. 18 (1), 2015
Number 17
VOL. 17 (2), 2014
Number 17
VOL. 17 (1), 2014
Number 16
VOL. 16 (2), 2013
Number 16
VOL. 16 (1), 2013
Number 15
VOL. 15 (2), 2012
Number 15
VOL. 15, 2012 Supplement
Number 15
Vol. 15 (1), 2012
Number 14
14 - Vol. 14 (2), 2011
Number 14
The 9th Balkan Congress of Medical Genetics
Number 14
14 - Vol. 14 (1), 2011
Number 13
Vol. 13 (2), 2010
Number 13
Vol.13 (1), 2010
Number 12
Vol.12 (2), 2009
Number 12
Vol.12 (1), 2009
Number 11
Vol.11 (2),2008
Number 11
Vol.11 (1),2008
Number 10
Vol.10 (2), 2007
Number 10
10 (1),2007
Number 9
1&2, 2006
Number 9
3&4, 2006
Number 8
1&2, 2005
Number 8
3&4, 2004
Number 7
1&2, 2004
Number 6
3&4, 2003
Number 6
1&2, 2003
Number 5
3&4, 2002
Number 5
1&2, 2002
Number 4
Vol.3 (4), 2000
Number 4
Vol.2 (4), 1999
Number 4
Vol.1 (4), 1998
Number 4
3&4, 2001
Number 4
1&2, 2001
Number 3
Vol.3 (3), 2000
Number 3
Vol.2 (3), 1999
Number 3
Vol.1 (3), 1998
Number 2
Vol.3(2), 2000
Number 2
Vol.1 (2), 1998
Number 2
Vol.2 (2), 1999
Number 1
Vol.3 (1), 2000
Number 1
Vol.2 (1), 1999
Number 1
Vol.1 (1), 1998

 

 


 About the journal ::: Editorial ::: Subscription ::: Information for authors ::: Contact
 Copyright © Balkan Journal of Medical Genetics 2006